A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

10.1038/s41408-022-00768-5

Saved in:

Bibliographic Details
Main Authors:	Chng, WJ, Lonial, S, Morgan, GJ, Iida, S, Moreau, P, Kumar, SK, Twumasi-Ankrah, P, Villarreal, M, Dash, AB, Vorog, A, Zhang, X, Suryanarayan, K, Labotka, R, Dimopoulos, MA, Rajkumar, SV
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	Springer Science and Business Media LLC 2023
Subjects:	Humans Multiple Myeloma Lenalidomide Dexamethasone Boron Compounds Chromosome Aberrations Antineoplastic Combined Chemotherapy Protocols
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/237477
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
by: Dimopoulos, Meletios A, et al.
Published: (2022)

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
by: Goldschmidt, Hartmut, et al.
Published: (2022)

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
by: Chng, W-J, et al.
Published: (2022)

ELUCIDATING THE ROLE OF ADAR1 IN REGULATING IMMUNOTHERAPEUTIC RESPONSE IN MULTIPLE MYELOMA
by: KOH MUN YEE
Published: (2023)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
by: Soekojo, Cinnie Yentia, et al.
Published: (2022)

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
by: Gupta, N, et al.
Published: (2020)

Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
by: Spencer, Andrew, et al.
Published: (2023)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
by: Chen, Yunxin, et al.
Published: (2021)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
by: Davies, FE, et al.
Published: (2023)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
by: Davies, FE, et al.
Published: (2023)

Centrosomes and myeloma; aneuploidy and proliferation
by: Chng, W.J., et al.
Published: (2016)

Natural history and prognostic factors at first relapse in multiple myeloma
by: Wang, C., et al.
Published: (2021)

Management of treatment-emergent peripheral neuropathy in multiple myeloma
by: Richardson, P.G., et al.
Published: (2016)

Extramedullary plasmacytoma of the orbit as initial presentation of multiple myeloma
by: Razak, R.A., et al.
Published: (2016)

The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
by: Tan, D., et al.
Published: (2016)

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
by: Moreau, P, et al.
Published: (2022)

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: An analysis of the Singapore multiple myeloma study group
by: Tan, D., et al.
Published: (2016)

CHARACTERISING THE METABOLIC PHENOTYPE OF C-MAF OVEREXPRESSION IN MULTIPLE MYELOMA
by: LIM SZE LYNN JULIA
Published: (2024)

MANAGING UNCERTAINTY IN ONCOLOGY DRUG ASSESSMENTS: APPLICATIONS IN MULTIPLE MYELOMA
by: DIANA BEATRIZ SAMSON BAYANI
Published: (2024)

Activities of the cytokine receptor CD137 in multiple myeloma
by: KOH LIANG KAI
Published: (2010)

Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma
by: Chng, W.-J., et al.
Published: (2014)

Multiple Myeloma-Associated Light Chain Amyloidosis and a Proposed Approach to Monoclonal Immunoglobulin-Associated Renal Disease
by: Zi Yun Chang, et al.
Published: (2020)

Nghiên cứu bào chế Gel tra mắt In Situ chứa Gentamicin 0,3 % và Dexamethason 0.1 %
by: Huỳnh, Thị Ngọc Diễm, et al.
Published: (2020)

A unique rhinologic manifestation of multiple myeloma
by: Seah, Jun Jie, et al.
Published: (2022)

Transmembrane activator and caml interactor (Taci): Another potential target for immunotherapy of multiple myeloma?
by: Xu, S., et al.
Published: (2021)

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival
by: Reghunathan, R., et al.
Published: (2014)

Qualitative study of factors affecting patient, caregiver and physician preferences for treatment of myeloma and indolent lymphoma
by: Jen, W.-Y., et al.
Published: (2021)

Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myeloma
by: Xie, Z., et al.
Published: (2014)

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL
by: Ueno, S., et al.
Published: (2011)

Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma
by: Yang, M.H., et al.
Published: (2021)

Suppression of essential pro-inflammatory signaling pathways by natural agents for the therapy of multiple myeloma
by: Sikka, S., et al.
Published: (2014)

ELUCIDATING THE ONCOGENIC ROLES OF MARCH5 IN MULTIPLE MYELOMA
by: HAMED BASHIRI
Published: (2024)

GENOME-WIDE PHARMACOLOGIC UNMASKING IDENTIFIES TUMOR SUPPRESSOR MICRORNAS IN MULTIPLE MYELOMA
by: BI CHONGLEI
Published: (2016)

Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade
by: Jung Y.Y., et al.
Published: (2019)

Sensitivity to inhibition by N-ethylmaleimide: A property of nitrobenzylthioinosine-sensitive equilibrative nucleoside transporter of murine myeloma cells
by: Lee, C.-W., et al.
Published: (2014)

Sensitivity to inhibition by N-ethylmaleimide: A property of nitrobenzylthioinosine-sensitive equilibrative nucleoside transporter of murine myeloma cells
by: Lee, C.-W., et al.
Published: (2016)

IDENTIFY FUNCTIONAL PROTEINS INTERACTING WITH MMSET IN MULTIPLE MYELOMA
by: CHOOI JING YUAN
Published: (2018)

Targeting nf-κb signaling for multiple myeloma
by: Wong, A.H.-H., et al.
Published: (2021)

IDENTIFICATION OF AN EFFECTIVE RIBONUCLEOSIDE ANALOGUE AND IMMUNOMODULATORY IMIDE DRUG COMBINATION FOR MULTIPLE MYELOMA
by: WEIJIE WANG
Published: (2024)

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
by: Liu, Jin, et al.
Published: (2022)